Search results
Showing 706 to 720 of 2208 results for guidelines
In development Reference number: GID-TA11477 Expected publication date: 26 August 2026
Evidence-based recommendations on SEM Scanner 200 for preventing pressure ulcers.
Awaiting development Reference number: GID-QS10035 Expected publication date: TBC
Alair bronchial thermoplasty system for adults with severe difficult to control asthma (MIB71)
NICE has developed a medtech innovation briefing (MIB) on the Alair bronchial thermoplasty system for adults with severe, difficult to control asthma
Evidence summaries: new medicines – Integrated process statement (PMG11)
This integrated process statement has been produced to explain how 'Evidence summaries: new medicines' (ESNMs) are developed. It provides an overview of the key process principles and describes all stages of the development of ESNMs
This indicator covers patient experiences of dental services. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
NICE has developed a medtech innovation briefing (MIB) on NATROX oxygen wound therapy for managing diabetic foot ulcers and complex or chronic non-healing wounds .
Diabetes mellitus type 1 and type 2: insulin glargine biosimilar (Abasaglar) (ESNM64)
Summary of the evidence on insulin glargine biosimilar (Abasaglar) for type 1 and type 2 diabetes mellitus to inform local NHS planning and decision-making
Alere Afinion CRP for C-reactive protein testing in primary care (MIB81)
NICE has developed a medtech innovation briefing (MIB) on the Alere Afinion CRP for C-reactive protein testing in primary care
Sole supplied titles are distinct journal and book collections that can be purchased from Lot 1 of our purchasing framework.
Evidence-based recommendations on ruxolitinib (Jakavi). This drug is for adults with disease-related splenomegaly or symptoms caused by primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis, only if they have intermediate-2 or high-risk disease.
Methadone and buprenorphine for the management of opioid dependence (TA114)
Evidence-based recommendations on methadone and buprenorphine (oral formulations) for managing opioid dependence in adults.
Linaclotide acetate for treating Chronic idiopathic constipation [TSID12005]
Topic prioritisation
Membership details, terms of reference, future meeting dates and past meeting minutes for our interventional procedures advisory committee.